
1,000+ offline pharmacy stores added in FY23.
Apollo Hospitals posted revenue from operations at Rs 4302.20 crore, up 21.3 per cent from Rs 3546.43 crore in the…
Timely monitoring of vital signs is essential to avoid further loss of life, especially when patients may not have access…
Dr. Nangia told Financial Express.com that this procedure is also available under various insurance schemes.
SGX Nifty hints at a muted start for benchmark indices NSE Nifty 50 and BSE Sensex. Vodafone Idea, ICICI Bank,…
The International Patient Safety Awards were presented during the conference to recognise excellence in various categories, including Digital Innovation, Patient…
The hospital group stated that around 150 Speakers and over 1200 delegates from 30 countries are expected to participate in…
Ewing’s Sarcoma is a rare type of cancer that occurs in bones or in the soft tissue around the bones.
According to the doctors, this is for the first time in the world that the principles of head and neck,…
Apollo ASP will implement evidence-based interventions overseen by a multidisciplinary collaborative Antimicrobial Stewardship Programme Committee, the doctors said.
According to a statement by Apollo Hospitals, the transaction consideration (including primary and secondary investment) is around Rs 26 crores.
Through the digital app, Apollo 24, another 500 million Indians can get their medicines delivered in 24 hours, Kamineni said.
A type of radiation therapy, Proton therapy uses high-powered energy to treat cancer and some noncancerous tumors.
Sangita Reddy, who has been till very recent also wearing the hat of the president of the Federation of Indian…
Technically, after three days’ uptrend rally, one more time the NIfty/Sensex took the resistance near 16000/53800.
Ebitda estimates for FY23/24 changed due to expansion, allied factors; Fortis is the top pick, followed by Max.
The team will conduct regular medical and quality audits to ensure patient safety at the Apollo-Imperial Hospital.
Execution stays impressive; valuations attractive after correction; upgraded to Buy with target price of Rs 4,710